From the publishers of JADPRO

DLBCL Resource Center

Advertisement

2024 American Society of Hematology Annual Meeting Abstract

Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes

2024 American Society of Hematology Annual Meeting Abstract

Real-world effectiveness of tafasitamab (Tafa) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in the United States

2024 American Society of Hematology Annual Meeting Abstract

Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed/refractory large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Open-label phase 2 study results of FS118, a LAG-3/PD-L1 bispecific antibody, in patients with relapsed/refractory diffuse large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Waveline-007: Dose escalation and confirmation, and efficacy expansion trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in patients with diffuse large B cell lymphoma

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

The Oncologist

Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma 

European Society for Medical Oncology (ESMO) Congress 2024 Abstract

806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)

Journal of Personalized Medicine

The evolving role of bispecific antibodies in diffuse large B-cell lymphoma

European Hematology Association Congress 2024 Abstract

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory diffuse large B-cell lymphoma: Results of a global randomized phase III trial (STARGLO)

New England Journal of Medicine

Combination targeted therapy in relapsed diffuse large B-cell lymphoma

Advances in Radiation Oncology

Combining obinutuzumab with radiation for refractory DLBCL: Retrospective safety and efficacy analysis

British Journal of Haematology

Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma—outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP

Cancer Medicine

Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy

2024 ASCO Annual Meeting Abstract

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

2024 ASCO Annual Meeting Abstract

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study

2024 ASCO Annual Meeting Abstract

Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6

OncLive

Glofitamab plus chemotherapy meets OS end point in R/R DLBCL

CPT: Pharmacometrics & Systems Pharmacology

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

Cancer Diagnosis & Prognosis

Clinical outcomes in patients with DLBCL treated with R-CHOP according to radiotherapy and interim PET response

Haematologica

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: A systematic review and meta-analysis

Journal of Patient-Reported Outcomes

Are changes in patient-reported outcomes prognostic for diffuse large B-cell lymphoma survival? Results from the GOYA trial

HemaSphere

Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

EJNMMI Research

Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients

ESMO Open

Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma

European Journal of Haematology

Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR

Current Oncology

Ibrutinib plus RCHOP versus RCHOP only in young patients with activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL): A cost-effectiveness analysis

British Journal of Haematology

The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline

Future Oncology

Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation

2023 American Society of Hematology Annual Meeting Abstract

Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study

2023 American Society of Hematology Annual Meeting Abstract

Subcutaneous epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma from EPCORE NHL-5

2023 American Society of Hematology Annual Meeting Abstract

Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume

HemaSphere

Clonal relationship and mutation analysis in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with diffuse large B-cell lymphoma

International Journal of Cancer

Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A population-based study

Frontiers in Oncology

Hepatitis B virus and B-cell lymphoma: Evidence, unmet need, clinical impact, and opportunities

Clinical Lymphoma, Myeloma, and Leukemia

ABCL-647 The outcome of tisagenlecleucel (tisa-cel) CD-19 CAR-T cell therapy in NHL relapsed/refractory beyond second line of therapy, single-center data

Clinical Lymphoma, Myeloma & Leukemia

Updated results from a rapcabtagene autoleucel (YTB323) phase I study demonstrate durable efficacy and a manageable safety profile in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Annals of Medicine

Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Blood Advances

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Annals of Hematology

Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma

Haematologica

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study

Transplantation and Cellular Therapy

Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma

The Lancet Haematology

Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study

Clinical and Molecular Hepatology

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma

Oncology Nursing News

Epcoritamab obtains accelerated approval for relapsed/refractory DLBCL

Cancers

Factors affecting health-related quality of life among survivors of non-Hodgkin lymphoma: A population-based study

Journal of Clinical Oncology

Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International metabolic prognostic index

Blood Cancer Journal

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Scientific Reports

Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma

U.S. Food and Drug Administration

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma

Cure

Targeted therapies shake up the DLBCL treatment paradigm, expert says

Transplantation and Cellular Therapy

Assessment of salvage regimens post CAR-T cell therapy for patients with diffuse large B-cell lymphoma

Cell Therapy Next

CAR-T poised to create ‘paradigm shift’ in non-Hodgkin lymphoma

Blood Cancer Journal

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

Oncology

Current Frontline Treatment of Diffuse Large B-Cell Lymphoma

Advances in Hematology

Safety and efficacy of subcutaneous rituximab in previously untreated patients with CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from an Italian phase IIIb study

New England Journal of Medicine

Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

Scientific Reports

Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma

2021 American Society of Hematology Annual Meeting (Abstract)

The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma

2021 American Society of Hematology Annual Meeting (Abstract)

Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3)

2021 American Society of Hematology Annual Meeting (Abstract)

Real-world efficacy and safety outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

2021 American Society of Hematology Annual Meeting (Abstract)

Tafasitamab plus lenalidomide versus Pola-BR, R2, and CAR T: Comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed/refractory diffuse large B-cell lymphoma

Oncology and Therapy

Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with Car T-cell therapy: A qualitative study

Cancers

Immunotherapy for diffuse large B-cell lymphoma: Current landscape and future directions

Targeted Oncology

R-Mini-CHOP plus ibrutinib demonstrates promising PFS in newly diagnosed DLBCL

CancerNetwork

Naratuximab emtansine/rituximab yields promising responses in DLBCL

Cancer Cell

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

Clinical Lymphoma, Myeloma & Leukemia

Health-related quality of life, symptoms, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma

Hematology/Oncology and Stem Cell Therapy

Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?

Clinical Lymphoma, Myeloma & Leukemia

ABCL-166: Tisagenlecleucel and lisocabtagene maraleucel: comparative efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma

Clinical Lymphoma, Myeloma & Leukemia

ABCL-022: LOTIS-2 follow-up analysis: updated results from a phase 2 study of loncastuximab tesirine (lonca) in relapsed or refractory diffuse large B-cell lymphoma

Society of Hematologic Oncology 2021 Annual Meeting (Poster)

Overall survival with tafasitamab + lenalidomide (LEN) vs routinely administered therapies for ASCT-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): outcomes from the observational RE-MIND2 study

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Rituximab and non-pegylated liposomial doxorubicin (R-NPLD) treatment in patients 80 years of age or older affected by diffuse large B-cell lymphoma (DLBCL): A 2020 update and implications of clinical and pathological factors

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

OncoImmunology

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

Cancers

Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Biologics: Targets and Therapies

Antibody therapies for large B-cell lymphoma

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management

Leukemia

Treatment resistance in diffuse large B-cell lymphoma

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

2021 European Hematology Association Virtual Congress (Abstract)

Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other non-Hodgkin’s B-cell lymphomas - a phase 2 study

2021 American Society of Clinical Oncology Annual Meeting (Abstract)

Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

2021 American Society of Clinical Oncology Annual Meeting (Abstract)

Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

2021 European Hematology Association Virtual Congress (Abstract)

Real-world treatment with CAR T-cell therapy of United States (US) patients with large B cell lymphoma (LBCL)

British Journal of Haematology

Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma

Blood Advances

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP

The Lancet Oncology

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Journal of Clinical Oncology

Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial

British Journal of Haematology

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Journal of Clinical Oncology

Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective Elderly Project of the Fondazione Italiana Linfomi

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Unraveling the Enigma: A Case Study on Primary CNS Lymphoma

Relapsed DLBCL After CAR T-Cell Therapy

Follicular Lymphoma Transformed to DLBCL

Fast Facts #12: Long-Term Survivorship